retatrutide mechanism of action retatrutide clinical trials 2024 2025 Diagram showing the of Retatrutide, an experimental weight-loss drug,

Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared

The second position of its N-terminus is glycine (alanine in GLP-1), which is not easily degraded by the DPP-4 enzyme

These potential benefits, however, come with high costs that raise concerns about the impacts on public and private payers

Maintaining healthy habits alongside medication can play an important role in achieving lasting results

Four individual GLP-1 receptor agonists have now demonstrated MACE superiority in their dedicated cardiovascular outcome trials: Liraglutide: LEADER trial Semaglutide: SUSTAIN-6 and the landmark SELECT trial Dulaglutide: REWIND trial Albiglutide: HARMONY trial The SELECT trial deserves special attention because it broke entirely new ground